Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...
ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...
NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...
In this episode of “iOpeners” from Ophthalmology Times, host Nicole Bajic, MD, comprehensive ophthalmologist at the Cole Eye Institute, Cleveland Clinic, speaks with Emily Schehlein, MD, about efforts ...
What it is. AXPAXLI (OTX-TKI) is an investigational, bioresorbable intravitreal hydrogel implant designed to continuously ...
BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating performance-based endpoints that map to mobility and object recognition. Enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results